Tenecteplase versus alteplase for acute ischaemic stroke in the elderly patients: a post hoc analysis of the TRACE-2 trial.

Yun-Yun Xiong Liyuan WangYuesong PanMengxing WangLee H SchwammChunmiao Duan Bruce C V Campbell Shuya Li Manjun HaoNa WuZhixin CaoShuangzhe WuZi-Xiao Li Yong-Jun Wang

Published in: Stroke and vascular neurology (2024)

The risk-benefit profile of tenecteplase thrombolysis was preserved in the elderly patients, which lends further support to intravenous 0.25 mg/kg tenecteplase as an alternative to alteplase in these patients.

Keyphrases

acute ischemic stroke
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease

prognostic factors
pulmonary embolism
high dose
study protocol
randomized controlled trial

phase iii
low dose
intensive care unit
respiratory failure
patient reported outcomes

drug induced
phase ii
aortic dissection
mechanical ventilation